Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uva ursi, derived from the leaves of the *Arctostaphylos uva-ursi* plant, is a traditional herbal remedy primarily used for the treatment of lower urinary tract infections (UTIs) and inflammatory conditions of the bladder. Its therapeutic activity is largely attributed to the phenolic glycoside arbutin. Upon oral ingestion, arbutin is hydrolyzed by intestinal bacteria to hydroquinone, which is subsequently absorbed, conjugated in the liver (primarily as glucuronides and sulfates), and excreted via the kidneys. In the presence of alkaline urine (pH > 7), these conjugates are hydrolyzed back into free hydroquinone, which exhibits potent antiseptic and antibacterial properties against common uropathogens such as *Escherichia coli* and *Staphylococcus aureus*. Due to the potential for hydroquinone-induced toxicity, including liver damage and ocular concerns with prolonged exposure, uva ursi is typically recommended for short-term use only.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on uva ursi.